Anxiety during examinations and similar conditions is a widespread phenomenon that very often leads to intake of drugs with considerable side effects. An alternative therapy might consist in using complex homeopathic medicines with a better tolerability. Among these, one preparation is based on nine mainly plant derived homeopathic triturations (potencies D2 to D8) and is marketed in Germany under the name of Calmvalera Hevert tablets for the treatment of nervous restlessness and sleep disorders including better coping with stress.
Many other preparations from herbal origin have been tested using neurophysiological techniques  -  . The present investigation aimed at the possibility, that Calmvalera Hevert tablets might be able to help subjects suffering from examination anxiety. In order to test this, a new design of a clinical study was used, namely “EnkephaloVision”. This new approach consists of the combination of quantitative EEG recording providing very high time resolution of epochs of 364 ms (Neurocode-Tracking) with conventional Eye-Tracking  .
There is convincing evidence that emotional states directly relate to brain electric activity in terms of spectral frequency changes  . Also, according to our experience, when presenting videos with emotional content, reproducible changes of brain electric activity have been recorded  . In the present study, twenty-four subjects suffering from examination (or test) anxiety were exposed audio-visually to 5 cognitive and 5 emotional challenges by asking for task performance and watching video clips of short durations. It was hoped that the drug would induce specific changes of electric features related to a calming action.
Twenty-four healthy male and female subjects aged 18 - 40 years were recruited by advertisements in newspapers. Using an anxiety questionnaire (Prüfungsangstfragebogen PAF-S from Hogrefe Verlag, Göttingen, Germany  ) only subjects having score values above 60 were selected to participate in the study. Score value 60 is the cut off for being healthy according to evaluation criteria of the test. Subjects must have been capable of giving informed consent. Subjects had to meet following exclusion criteria:
Acute or chronic disease with an impact on the study, which becomes obvious by case history or clinical examination (i.e. also Hamilton depression scale).
Clinically relevant pathological findings from clinical and laboratory findings.
Clinically relevant allergic symptoms.
Detection of alcohol at the time of initial examination (screening day SC) or on study day A (positive alcohol test) or by case history. Detection of drugs (positive drug test) at the time of initial examination (screening day SC).
Consumption of clinically relevant medication during last fourteen days before and during the active study period based on the notification of the subject or his case history.
Consumption of medication with primarily central action (i.e. psychotropic drugs or centrally acting antihypertensives). Known intolerance/hypersensitivity (allergy) to plant derived extracts (Cimicifuga, Cocculos, Passiflora, Valeriana etc.) or any of the ingredients of the investigational product (anamnestic). Presence of a rare genetic disease such as fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficiency (anamnestic).
BMI (Body Mass Index) <18 or >32.
Consumption of unusual quantities or misuse of coffee (more than 4 cups a day), tea (more than 4 cups a day) or tobacco (more than 20 cigarettes per day).
Smoking on study day A.
Participation in another clinical trial within the last 60 days.
Positive pregnancy test (study day A).
Cancellation of informed consent.
2.2. Trial Medication
Each subject was asked for intake of 6 tablets (daily dosage) at a time. The subjects selected for the study had a normal physical examination, electrocardiogram (ECG) and blood count for safety reasons. Laboratory tests for safety are listed in Table 3. Average age of the subjects was 24.88 ± 4.21 years.
2.3. Quantitative EEG
EnkephaloVision is the term for the entirely new combination of quantitative EEG (Neurocode-Tracking) and Eye-Tracking.
In this study a 17-channel EEG recording was combined with Eye-Tracking. Details
Table 1. Calmvalera hevert-tablets (registration No. 77957.00.00-product insert: November 2014).
Other ingredients: lactose-monohydrate (35 mg), magnesium stearate (Ph. Eur.), corn starch.
Table 2. Content of placebo tablets.
Table 3. Schedule of examinations and procedures.
of the EEG recording have been published earlier  but a new modified software for analysis of shorter time epochs of 364 ms duration was used (neo-CATEEM®, supplied by MEWICON CATEEM-Tec GmbH, 4164 Schwarzenberg am Böhmerwald, Austria). A manuscript containing details and validation of the software package―now called “Neurocode-Tracking”―has been published  . In short: For the new approach EEG frequency ranges to be analyzed had to be adjusted slightly to give the following exact ranges. Delta: 1.375 - 4.125 Hz; Theta: 4.125 - 6.875 Hz; Alpha1: 6.875 - 9.625 Hz; Alpha2: 9.625 - 12.375 Hz; Beta1: 12.375 - 17.875 Hz; Beta2: 17.875 - 34.375 Hz. This adjustment is a precondition for the new fast dynamic frequency analysis (Neurocode- Tracking) because under this condition each frequency range from delta up to alpha2 contains only one frequency (middle frequency within the particular frequency band). Data were analyzed in the current source density mode. All other features remained identical to the classic analysis used now for nearly 20 years. Maps were constructed by transforming spectral power values into spectral colors followed by additive color mixture (RGB-mode like in TV).
EEG recording was performed in the presence of a video clip, which contained several different cognitive and emotional challenges in series. At the beginning, after a gong for synchronization purposes, one minute was recorded under relaxation (eyes open) as reference, followed by presentation of a fixation cross. After this several cognitive and emotional challenges were presented: The total video was presented before and after intake of 6 tablets with some changes of cognitive tasks for prevention of memorized results. Between baseline recording and intake of Calmvalera Hevert or placebo tablets subjects had a pause for 90 minutes in the restroom. The time line of consecutive scenes is documented in the following Table 4.
Table 4. Time line of consecutive presentations.
Eye-Tracking (equipment and software from Tobii Technology GmbH, Frankfurt, Germany), was performed concomitantly with Neurocode-Tracking (fast dynamic quantitative EEG recording). All mental and emotional challenges were presented as a single video clip. Single challenges were first constructed as a power point file and then converted into a final video clip (by Adobe Captivate software). For offline analysis and synchronization with the eye-track data a screen grabber (Adobe Captivate software) was used to produce a video containing all successively calculated EEG maps of 364 ms duration. A second video was obtained from the eye-tracker software running on a separate computer. It is called a “gaze overlay” movie depicting the presented pictures, tasks or video film. In this gaze overlay video the momentary gaze of the subject is documented by a red spot. Data from the whole group are depicted as so-called heat maps. The presentation always started with an audio signal (gong). This audio signal was registered by screen capture of the EEG computer and was used for synchronization of both videos by means of a video cut software (Adobe Premiere Pro). Due to the processing time of the brain (300 to 400 ms) plus that of the computer (depends individually on the type and number of active processors!) the gaze overlay video is shifted in our case (quad core, 3.4 Giga-Hz) for one second in order to obtain synchronized images between gaze and the particular EEG epoch of 364 ms. For detailed offline documentation a movie was exported and analyzed image by image. Single representative images containing the gaze and corresponding EEG map were cut from the screen by a software tool available on all computers.
2.5. Experimental Design
On the experimental day (Day A), subjects started with a standardized breakfast. After this two questionnaires had to be filled out: Hamilton depression scale (HAMD)  and Hamilton anxiety scale (HAMA)  before randomization took place. Then, Enkephalo Vision session was started. A time line is given in Figure 1.
EEG data from the first recording session before intake of the capsules are given as ab-
Figure 1. Time line of procedures on experimental day (Day A). Subject in lounge: 90 minutes.
solute numbers (µV2). For explorative statistical evaluation the nonparametric Wilcoxon test was used. For mathematical differentiation of the different mental loads the linear discriminant analysis according to Fischer was used. Results from the first three discriminant functions were projected into space (X, Y and Z coordinates), whereas results from the fourth to sixth discriminant functions were coded into red, green and blue color, respectively, followed by an additive color mixture (so-called RGB-mode). In order to document statistically the different electric reaction of the brain to various cognitive and emotional loads, data from each part of the presentation were divided by the data obtained during recording of a relaxed state with eyes open (1 minute) at the beginning. Comparison of Calmvalera Hevert tablets versus placebo was accomplished by evaluation of the second recording of the day 90 minutes after intake. Data from the first recording (baseline) were set to 100% and electrophysiological changes produced by placebo or Calmvalera Hevert tablets are depicted as %-changes thereof. Sample size was defined according to several earlier studies performed under identical conditions.
2.7. Ethics and Authority Approval
The study was conducted according to the protocol after approval by the BfArM (Bonn, Germany) and Ethikkommission (Landesärztekammer Frankfurt, Germany) (PP_5014 _HEVERT_FINAL V1.0_23042015) and “Amendment 1 for PP_5014_HEVERT_FIN AL V1.0 _23042015”.
3. Quantitative EEG and Hamilton Anxiety Questionnaire
3.1. Basic Considerations
Twenty-four subjects were recruited for this study on the base of filling out a questionnaire dealing with examination anxiety. Concomitant presentation of a series of mental and emotional challenges during recording of the EEG was performed before and 90 minutes after intake of 6 Calmvalera Hevert tablets or placebo. The absolute starting values of spectral power in the six frequency ranges (delta to beta2) are given in Table 5. These values do not differ from each other in a statistically significant way suggesting that both groups placebo and verum have a similar starting position. This allows for a pre-post comparison of drug action. These absolute values are set to 100% and drug induced changes are documented in % of these starting values.
In order to relate the result from the anxiety questionnaire “HAMA” with EEG parameters a correlation was searched based on the first recordings before administration of the drug. The result indicates that absolute spectral alpha power from all 24 subjects during the recording condition “eyes open” in a relaxed state before drug administration correlated with the score values of the questionnaire. Figure 2 and Figure 3 document the results of this analysis showing a correlation coefficient r= −0.418 (p < 0.017) for alpha1 and r = −0.329 (p < 0.084) for alpha 2 spectral power.
3.2. Spectral Frequency Changes during Audio-Visual Challenges
Next step in the analysis was to find out if the different cognitive and visually presented
Figure 2. Correlation between HAMA anxiety questionnaire (score on abscissa) and spectral alpha1 power during the recording condition “eyes open” before drug intake. Spectral power was averaged including Cz, F3 and F4 electrode positions. Correlation coefficient (r = −0.418; p = 0.017).
Table 5. Spectral power before intake of placebo/verum (Pl/Ve) with respect to 17 locations under the recording condition “eyes open” before acute intake at day A. Comparison of the absolute starting values of both groups of subjects. Data are given as µV2 within each frequency range (delta-beta2). Med = median value. Electrode positions according to the so-called 10/20 system  . Pl = placebo; Ve = Calmvalera Hevert tablets.
Figure 3. Correlation between HAMA anxiety questionnaire (score on abscissa) and spectral alpha2 power during the recording condition “eyes open” before drug intake. Spectral power was averaged including Cz, F3 and F4 electrodes. Correlation coefficient (r = −0.329; p = 0.084).
emotional challenges lead to consistent changes of spectral power. For this purpose, data from each challenge were averaged over the presentation time in order to follow each of the brain regions with respect to the pattern of spectral power changes with respect to each frequency. In order to evaluate challenge specific changes of spectral power each challenge was calculated against the “eyes open” condition in order to eliminate unspecific responses. As expected, highly statistically significant increases of spectral power in the delta, theta and beta range were observed during all challenges. An overview on the statistical significance of the regional distribution of spectral power enhancement in comparison to the recording condition “eyes open” is documented in Figure 4(a) and Figure 4(b) for cognitive challenges and Figure 5(a) and Figure 5(b) for emotional challenges.
There is wide believe that the two brain hemispheres can function independently from each other. We therefore have analyzed the frequency changes in the presence of all challenges for each hemisphere in separate. The result is documented in Table 6 and Table 7. In general, the challenges led to statistically significant increases of delta (occasionally also theta) and beta2 spectral power in comparison to the recording condition “eyes open”. As one can see, there are some differences like the extent of delta and beta2 spectral power under the recording condition “eyes open”. During presentation of emotional pictures higher beta2 power is seen in the left hemisphere. Watching the examination video clip also leads to stronger enhancement of beta2 power in the left hemisphere. The largest difference with respect to beta2 power between the hemispheres was observed during the horror video. Regarding now the effects of all challenges with respect to single hemispheres strongest involvement of delta waves is recognized in both hemispheres.
Figure 4. Statistical maps for the regional significance of spectral frequency changes during performance of cognitive tasks. Statistical significance (sign-test) in comparison to the relaxed state is documented by the size of the small boxes (lowest part of the image).
4. Efficacy of Calmvalera Hevert Tablets on Challenge Induced Spectral Frequency Changes
4.1. Documentation of Spectral Changes at Single Scenes of the Challenges
First impressions of the effectiveness of Calmvalera Hevert tablets are obtained during single scenes of the presented challenges like emotional images (example: Figure 6), video clips (example: Figure 7). In order to uncover the influence of Calmvalera Hevert tablets under the different recording conditions identical single scenes were docu-
Figure 5. Statistical maps for the regional significance of spectral frequency changes during emotional challenges. Statistical significance (sign-test) in comparison to the relaxed state is documented by the size of the small boxes (lowest part of the image).
Table 6. Overview on changes in spectral power induced by all challenges with respect to all frequencies. Data are given in µV2 for the left brain area (combination of all left side electrodes F3,7 T3,5 P3 C3 O1). Statistical significance (sign-test) in comparison to “eyes open” recording condition is indicated as “p<” beneath the spectral power given in µV2.
mented before and after intake of the drug. The spectral power of all regions was looked at in terms of possible changes. A first impression was that alpha1 as well as alpha2 spectral power had increased in regions like the temporal lobe (yellow bars in Figure 6). An example recorded during watching the video “the dentist” is documented in Figure 7. Here stronger alpha1 activity is seen at central and temporal regions.
4.2. Group Analysis of Spectral Changes in the Presence of Calmvalera Hevert Tablets with Respect to Single Challenges
Quantitative analysis of frequency changes induced by Calmvalera Hevert tablets with respect to different brain regions revealed a statistically significant increase of apha1
Table 7. Overview on changes in spectral power induced by all challenges with respect to all frequencies. Data are given in µV2 for the right brain hemisphere (combination of all right side electrodes F4,8 T4,6 P4 C4 O2). Statistical significance (sign-test) in comparison to “eyes open” recording condition is indicated as “p<” beneath the spectral power given in µV2.
and alpha2 spectral power at electrode positions F3, C3, P3, T3 and O1 already under the recording condition “eyes open” as depicted in Figure 8. Remarkably, these electrode positions represent all areas on the left hemisphere (uneven numbers). There are also minor increases on the right hemisphere (even numbers) but none became statistically significant. Colors of the maps shift into a more yellow green direction as consequence of increased alpha activity.
When subjects were concentrating their attention on a fixation cross for one minute again alpha1 and alpha2 spectral power increases emerged nearly at the same electrode positions plus at F4 and F8 on the right hemisphere in a significant manner in comparison to placebo. An overview is given in Figure 9. Again colors of the maps shift into a more yellow green direction as consequence of increased alpha activity stronger within the left hemisphere (right side).
Figure 6. Representative scene (364 ms) from an emotional picture (upper image: at baseline (0 h)), lower image: 90 min after intake of 6 tablets of Calmvalera Hevert (group verum subject 003). Note increase of alpha power at electrode position T5.
Figure 7. Comparison of an arbitrarily chosen but representative single scene (364 ms). Data were averaged for all 12 subjects of the placebo group (left images) and verum group (right images). Eye-track results are depicted in the upper windows as so-called “heatmap”. EEG data are depicted in the lower windows. Frequency changes are documented within the bar graphs. Delta waves are coded into red, theta into orange, alpha1 into yellow, alpha2 into green, beta1 into turquoise, beta2 into blue. Please note decrease of beta (blue) and increase of alpha1 power (yellow) after intake of Calmvalera Hevert tablets (right image).
A very similar pattern was observed when watching the video “at the dentist”. Highest increases of alpha spectral power appeared at electrode position C3, followed by F3 and O1. Under this recording condition also Pz and T6 showed very slight, but statistically significant increases as documented in Figure 10. Due to increases of alpha activity dominant prevalence of yellow-green colors is observed within the left hemisphere (map right side of the image).
Analysis of the spectral power changes during watching the video dealing with an emergency surgery in the bush (Horror-OP) again revealed largest increases of alpha2 power at electrode positions C3 and O1. Minor but still significant increases were seen at C4, O2 and T6. An overview on changes with respect to all brain areas is given in Figure 11. Please note yellow-green spot in the map due to stronger focal alpha activity.
During performance of a cognitive task like the “Picture Comparison” again electrode positions C3 and O1 showed high statistically significant increases of alpha power. In addition, some increase of beta power emerged at electrode positions C3, T3 and O1. Data are documented in Figure 12. With respect to the map increased alpha activity is
Figure 8. Spectral power differences (recording condition “eyes open”) in comparison to the pre- drug period (set to 100%) 90 min after intake of placebo or verum (Calmvalera Hevert tablets) in all brain regions represented by the electrode positions: C = central, P = parietal, O = occipital, F = frontal, T = temporal. Even numbers are located in the right hemisphere, uneven numbers in the left one. Frequencies: red = delta, orange = theta, yellow = alpha1, green = alpha2, turquoise = beta1 and blue = beta2. Statistical significance (wilcoxon-test) between placebo and verum is indicated by stars. * = p < 0.10; ** = p < 0.05; *** = p < 0.01.
observed in frontal parts of the brain at interpolated regions indicated by predominating yellow and/or green color (more in the left hemisphere).
4.3. Effect of Calmvalera Hevert on the Spectral Power with Respect to Brain Hemispheres
Since right and left hemisphere reacted in a somewhat quantitatively different way to several challenges, they were analyzed separately with respect to an action of Calmvalera Hevert tablets in comparison to placebo. Regarding spectral delta and theta spectral activity virtually no effects were seen except for a tiny increase of theta power when watching emergency surgery (Horror-OP). Strongest statistically significant changes were observed in the alpha frequencies during several challenges as depicted in Figure 13 for the left hemisphere. However, there were also some minor but statistically sig-
Figure 9. Spectral power differences (recording condition “fix cross”) in comparison to the pre- drug period (set to 100%) 90 min after intake of placebo or verum (Calmvalera Hevert tablets) in all brain regions represented by the electrode positions: C = central, P = parietal, O = occipital, F = frontal, T = temporal. Even numbers are located in the right hemisphere, uneven numbers in the left one. Frequencies: red = delta, orange = theta, yellow = alpha1, green = alpha2, turquoise = beta1 and blue = beta2. Statistical significance (wilcoxon-test) between placebo and verum is indicated by stars. * = p < 0.10; ** = p < 0.05; *** = p < 0.01.
nificant increases of beta1 power and one result in beta2 power. Statistically significant spectral changes within the right hemisphere were only observed in the alpha1 range during watching the fix cross (p < 0.1), in the alpha2 range during watching the fix cross (p < 0.05) and the horror video (p < 0.05). Finally, beta1 spectral power had increased again during looking at the fix cross (p < 0.1).
4.4. Discriminant Analysis of Whole Data Set with Comparison to Other Drugs
Finally, all 102 parameters (17 electrode positions × 6 frequency ranges) were fed into a linear discriminant analysis for comparison with other drugs. As documented in Figure 14 the effect of Calmvalera Hevert tablets (verum) was projected at a considerable distance to the effect of its placebo (Figure 13) proving its fast effectiveness within 90 min
Figure 10. Spectral power differences (recording condition “dentist pain”) in comparison to the pre-drug period (set to 100%) 90 min after intake of placebo or verum (Calmvalera Hevert tablets) in all brain regions represented by the electrode positions: C = central, P = parietal, O = occipital, F = frontal, T = temporal. Even numbers are located in the right hemisphere, uneven numbers in the left one. Frequencies: red = delta, orange = theta, yellow = alpha1, green = alpha2, turquoise = beta1 and blue = beta2. Statistical significance (wilcoxon-test) between placebo and verum is indicated by stars. * = p < 0.10; ** = p < 0.05; *** = p < 0.01.
after intake. Interestingly, another homeopathic drug (Neurexan®) and a plant derived preparation (Neuravena®), both prescribed for the same indication as Calmvalera Hevert tablets, are projected into close vicinity of Calmvalera Hevert tablets (verum in Figure 14).
5. Effect of Calmvalera Hevert on Performance of Psychometric Tasks
Analysis of the performance of the psychometric tests did not reveal an influence of Calmvalera Hevert tablets when comparing to baseline values or after intake of placebo or verum as documented in Table 8. Slightly higher values after intake of the preparations were not statistically significantly different in any of the groups.
Figure 11. Spectral power differences (recording condition “horror-op”) in comparison to the pre-drug period (set to 100%) 90 min after intakeof placebo or verum (Calmvalera Hevert tablets) in all brain regions represented by the electrode positions. C = central, P = parietal, O = occipital, F = frontal, T = temporal. Even numbers are located in the right hemisphere, uneven numbers in the left one. Frequencies: red = delta, orange = theta, yellow = alpha1, green = alpha2, turquoise = beta1 and blue = beta2. Statistical significance (wilcoxon-test) between placebo and verum is indicated by stars: * = p < 0.10; ** = p < 0.05; *** = p < 0.01.
The present investigation contained an entirely new approach with respect to drug studies by using a combination of fast dynamic EEG analysis named “Neurocode-Trac- king” in combination with Eye-Tracking  now available under the term “Enkephalo Vision”. Using this new experimental design electric brain activity was monitored in the presence of several cognitive and emotional challenges. These challenges induced statistically significant frequency changes in the delta, theta and beta range, but rarely in the alpha range in comparison to the relaxed state (recording condition “eyes open”) with respect to both brain hemispheres. Beta activity was generally lower in the right hemisphere.
Figure 12. Spectral power differences (recording condition “picture comparison”) in comparison to the pre-drug period (set to 100%) 90 min after intake of placebo or verum (Calmvalera Hevert tablets) in all brain regions represented by the electrode positions. C = central, P = parietal, O = occipital, F = frontal, T = temporal. Even numbers are located in the right hemisphere, uneven numbers in the left one. Frequencies: red = delta, orange = theta, yellow = alpha1, green = alpha2, turquoise = beta1 and blue = beta2. Statistical significance (wilcoxon-test) between placebo and verum is indicated by stars. * = p < 0.10; ** = p < 0.05; *** = p < 0.01.
Interpretation of spectral EEG changes depends on the recording conditions. For example, general increases of delta activity during relaxation indicate sleepiness and usually are observed during sleep  . However, significant focal increases of spectral delta power have been observed during cognitive activity   . Our results show statistically significant increases of delta power when compared to the relaxing condition not only during performance of cognitive tasks but also during emotional challenges, thus confirming the results of a recent study using the identical design of “EnkephaloVision”  . General increases of theta power have been recognized as indicators of drowsiness and degraded vigilance under the condition of relaxation  . On the opposite, focal increases of theta power were reported to occur in frontal brain during increases of cortical activation in conditions of cognitive demands  -  . Our results are in line with these reports.
Figure 13. Effect of placebo (grey column) or verum (Calmvalera Hevert tablets = red column) on spectral power during different challenges averaged on selected electrode positions (F3,7 C3 T3,5 P3 O1) representing the left hemisphere. Data are given as % of baseline (0h, ref = reference) before intake. Statistical significance (wilcoxon-test) between placebo and verum is indicated by stars. * = p < 0.1; ** = p < 0.05; *** = p < 0.01.
Figure 14. Result of discriminant analysis based on all brain regions and frequencies 90 minutes after intake of Calmvalera Hevert tablets (verum). Results from the first three discriminant functions are depicted with the space coordinates x, y and z. Results from the next three discriminant functions are depicted as RGB colour mixture like in TV technology. Difference to baseline is taken for each drug. Diazepam and Fluoxetine are looked at 1 hour after intake, Hypericum 2 hours, all other preparations 3 hours after intake.
Increases of alpha activity have been related to relaxation and calmness in the past as reported in the literature  . Large increases of alpha1 activity were observed also in the presence of anti-anxiety drugs i.e. during treatment of schizophrenia  . Enhancement of alpha waves has also been observed during meditation  . Recent results show, that when alpha power increases, bold connectivity (functional nuclear magnetic resonance imaging (f NMRI)) between the primary visual cortex and occipital brain region decreases and that the negative relation of the visual cortex with the anterior/medial thalamus decreases and the ventral-medial pre-frontal cortex is reduced in strength  . Changes of alpha2 spectral activity are associated with mental workload   .
Comparing now the electric brain patterns before and 90 minutes after intake of six tablets of Calmvalera Hevert there was no influence on spectral delta, theta or beta ac tivity, in general. Calmvalera Hevert did not disturb psychometric performance. However, a statistical significant increase of alpha1 and alpha2 activity was observed in the presence of Calmvalera Hevert during several of the challenges, especially within the left hemisphere. Prevalence of alpha activity is regarded as a safe indicator of higher relaxation and less anxiety as mentioned above. This means that the brain is protected by a disconnection of the electrical circuits between these brain areas. Thus, increases of alpha power induced by Calmvalera Hevert tablets speak in favor of a calming and protective effect and provides objective proof of the action against nervousness and stress Interpretation of such biological surrogate parameters has been supported and reported also by others  . Finally, discriminant analysis confirmed statistically the quick and efficient effectiveness of Calmvalera Hevert tablets in comparison to other drugs or.
Table 8. Mental performance in cognitive tests before and after intake of 6 tablets Calmvalera Hevert (verum) or placebo. No statistical differences were observed between verum and placebo.
herbal preparations. Projection of the EEG data of Calmvalera Hevert tablets into the close vicinity of Neurexan® (a homeopathic drug with proven relaxing properties) and Neuravena® (a plant-derived drug marketed for its relaxing property) point to a similar calming action.
A limitation of the study might be seen in the fact that results from the psychometric testing only revealed a positive tendency in the presence of Calmvalera tablets in comparison to placebo. Possibly, statistical significances would have been obtained by including higher numbers of subjects. Due to the low triturations (D2 to D8) of the ingredients of Calmvalera tablets, their efficacy points to the content of highly active molecules in one or more of the single ingredients. Evidence for this hypothesis stems from the preclinical in vivo and in vitro pharmacological characterization of other low homeopathic triturations like for example obtained from Gelsemium and Veratrum  . Especially active ingredients from the D3 triturations of Cimicifuga and Passiflora incarnata might be responsible for the observed effects.
Using the new clinical design “EnkephaloVision”, experiments provide evidence, that the homeopathic Calmvalera Hevert tablets are obviously able to change the electric activity of the brain in a statistically significant manner in comparison to placebo. Ninety minutes after intake of 6 tablets (daily dosage) increases of spectral alpha power were observed during relaxation and most of audiovisual challenges in comparison to baseline. Since increases of alpha power are related to higher calmness, efficacy of the homeopathic Calmvalera Hevert tablets is shown by a biological surrogate parameter for relaxation. Comparison to other drugs using discriminant analysis shows, that present data obtained for Calmvalera tablets are projected into the vicinity of other plant-deri- ved calming preparations. Efficacy of Calmvalera tablets point to highly active molecules contained in low triturations (D2 - D8) of this preparation.
Mrs. Ingrid K. Keplinger-Dimpfel is thanked for performance of the logistics of the study and quality control. We greatly appreciate the experimental work as well as the data documentation performed by Mrs. Leonie Schombert.
 Dimpfel, W., Pischel, I. and Lehnfeld, R. (2004) Effects of Lozenge Containing Lavender Oil, Extracts from Hops, Lemon Balm and Oat on Electrical Brain Activity of Volunteers. European Journal of Medical Research, 9, 423-431.
 Dimpfel, W., Kler, A., Kriesl, E., Lehnfeld, R. and Keplinger-Dimpfel, I.K. (2006) Neurophysiological Characterization of a Functionally Active Drink Containing Extracts of Ginkgo and Ginseng by Source Density Analysis of the Human EEG. Nutritional Neuroscience, 9, 213-224.